The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort
Abstract
OBJECTIVE: To determine efficacy and safety of rituximab treatment as a second-line immunotherapy treatment for autoimmune limbic encephalitis (ALE) and to determine factors associated with functional improvement and favorable outcome following rituximab treatment. METHODS: We recruited 80 patients with ALE who were treated with rituximab as a second-line immunotherapy from the Korea Autoimmune Synaptic and Paraneoplastic Encephalitis Registry and reviewed 81 patients without rituximab as a control. We grouped patients according to the detection or type of antibodies; in addition, we evaluated clinical, laboratory, first-line immunotherapy, and rituximab treatment profiles and defined main outcomes as improvements on the modified Rankin Scale (mRS) score and a favorable mRS score (0-2) at the last follow-up. RESULTS: Functional improvement occurred more frequently in the rituximab group compared to the control group. In the rituximab group, 30 (37.5%) patients had synaptic autoantibodies, 15 (18.8%) in the paraneoplastic autoantibodies, and 35 (43.8%) were antibody-negative. The effect of rituximab was the same regardless of autoantibody status. Additional monthly rituximab therapy and partial response to first-line immunotherapies were associated with mRS score improvements, as well as favorable mRS scores. mRS scores of 4-6 as the worst neurologic status predicted an unfavorable mRS score. There were no reported serious infusion-related or infectious adverse effects of rituximab. CONCLUSIONS: Rituximab is effective and safe as a second-line immunotherapy for ALE, regardless of autoantibody status. Additional monthly rituximab therapy might potentiate the efficacy of rituximab. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that rituximab improves mRS scores for patients with autoimmune limbic encephalitis who fail first-line therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488
Titulaer, M. J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., Honig, L. S., Benseler, S. M., Kawachi, I., Martinez-Hernandez, E., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70310-1 · Cited by 3,165 · cited 5×
“First-line immunotherapy consisted of corticosteroids, IV immunoglobulins (IVIg), and plasmapheresis.(20) We defined 1 cycle of immunotherapy as 500–1,000 mg of methylprednisolone for 5 days, 0.”
BackgroundMethodResultInfluentialParaneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
Dalmau, J., Tüzün, E., Wu, H., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J. M., Shimazaki, H., Koide, R., King, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21050 · Cited by 2,492
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Tunkel, A. R., Glaser, C. A., Bloch, K. C., Sejvar, J. J., Marra, C. M., Roos, K. L., Hartman, B. J., Kaplan, S. L., Scheld, W. M., & Whitley, R. J. (2008) · Clinical Infectious Diseases · doi:10.1086/589747 · Cited by 1,193
Irani, S. R., Bera, K., Waters, P., Zuliani, L., Maxwell, S., Zandi, M. S., Friese, M. A., Galea, I., Kullmann, D. M., Beeson, D., et al. (2010) · Brain · doi:10.1093/brain/awq113 · Cited by 1,035
Cited by
Autoantibodies in neurological disease
Prüss, H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00543-w · Cited by 319
Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study
Lee, W.-J., Lee, S.-T., Moon, J., Sunwoo, J.-S., Byun, J.-I., Lim, J.-A., Kim, T.-J., Shin, Y.-W., Lee, K.-J., Jun, J.-S., et al. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0442-6 · Cited by 271
Self-citationTreatment strategies for autoimmune encephalitis
Shin, Y.-W., Lee, S.-T., Park, K.-I., Jung, K.-H., Jung, K.-Y., Lee, S. K., & Chu, K. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617722347 · Cited by 266
Self-citationDevelopment of the clinical assessment scale in autoimmune encephalitis
Lim, J., Lee, S., Moon, J., Jun, J., Kim, T., Shin, Y., Abdullah, S., Byun, J., Sunwoo, J., Kim, K. T., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25421 · Cited by 253
Self-citationWesselingh, R., Butzkueven, H., Buzzard, K., Tarlinton, D., O'Brien, T. J., & Monif, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02066 · Cited by 83
Metadata
- Authors
- Lee, W.-J., Lee, S.-T., Byun, J.-I., Sunwoo, J.-S., Kim, T.-J., Lim, J.-A., Moon, J., Lee, H. S., Shin, Y.-W., Lee, K.-J., Kim, S., Jung, K.-H., Jung, K.-Y., Chu, K., & Lee, S. K.
- Venue
- Neurology
- Published
- 2016-05-03
- Volume
- 86
- Issue
- 18
- Pages
- 1683-1691
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2319091176
- Cited by
- 195
- References
- 6
- FWCI
- 12.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. https://app.cochat.ai/papers/10.1212/wnl.0000000000002635
- The paper
- Lee, W.-J., Lee, S.-T., Byun, J.-I., Sunwoo, J.-S., Kim, T.-J., Lim, J.-A., Moon, J., Lee, H. S., Shin, Y.-W., Lee, K.-J., Kim, S., Jung, K.-H., Jung, K.-Y., Chu, K., & Lee, S. K. (2016). Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology. https://doi.org/10.1212/wnl.0000000000002635
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.